Intellia Therapeutics, Inc. (NTLA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Intellia Therapeutics (NTLA) Q4 2025: Lombosi Phase 3 Enrollment Surpasses 80, Paving Path to First CRISPR Launch
February 26, 2026
-
Intellia Therapeutics (NTLA) Q3 2025: Clinical Hold Disrupts NEXE Progress as 650+ Patient Data Underpins Safety Analysis
November 07, 2025
-
Intellia (NTLA) Q2 2025: Magnitude Trial Expands 57% to 1,200 Patients, Sharpening Competitive Edge
August 07, 2025
-
Intellia (NTLA) Q1 2025: Phase 3 Enrollment Surges Past 90 Sites, Accelerating Path to First Launch
July 07, 2025